CYP19A1 and Dyspareunia: The quantitative synthesis of our findings proved GnRH antagonists to be the most effective for dysmenorrhea, CHCs in the treatment of dyspareunia, and for overall pelvic pain, CHCs or progestins combined with aromatase inhibitors.